GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RVL Pharmaceuticals PLC (OTCPK:RVLPQ) » Definitions » Dividend Yield %

RVL Pharmaceuticals (RVL Pharmaceuticals) Dividend Yield % : 0.00% (As of Jun. 06, 2024)


View and export this data going back to 2018. Start your Free Trial

What is RVL Pharmaceuticals Dividend Yield %?

As of today (2024-06-06), the Trailing Annual Dividend Yield of RVL Pharmaceuticals is 0.00%.

The historical rank and industry rank for RVL Pharmaceuticals's Dividend Yield % or its related term are showing as below:

RVLPQ's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.63
* Ranked among companies with meaningful Dividend Yield % only.

RVL Pharmaceuticals's Dividend Payout Ratio for the three months ended in Jun. 2023 was 0.00.

As of today (2024-06-06), the Forward Dividend Yield % of RVL Pharmaceuticals is 0.00%.

RVL Pharmaceuticals's Dividends per Share for the three months ended in Jun. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


RVL Pharmaceuticals Dividend Yield % Historical Data

The historical data trend for RVL Pharmaceuticals's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RVL Pharmaceuticals Dividend Yield % Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Dividend Yield %
Get a 7-Day Free Trial - - - - -

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Dividend Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of RVL Pharmaceuticals's Dividend Yield %

For the Biotechnology subindustry, RVL Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RVL Pharmaceuticals's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where RVL Pharmaceuticals's Dividend Yield % falls into.



RVL Pharmaceuticals Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


RVL Pharmaceuticals  (OTCPK:RVLPQ) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


RVL Pharmaceuticals Dividend Yield % Related Terms

Thank you for viewing the detailed overview of RVL Pharmaceuticals's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


RVL Pharmaceuticals (RVL Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
Executives
Foundation Harsaul 10 percent owner EDIFICIO AFRA, AVENIDA SAMUEL LEWIS Y CALLE 54, PANAMA R1
Altchem Ltd 10 percent owner KARAISKAKI 6, CITY HOUSE, LIMASSOL G4 3032
Alisa Lask director C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079
David F Burgstahler director, 10 percent owner C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Athyrium Opportunities Associates Iv Co-invest Llc 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Associates Iv Gp Llc 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Co-invest 2 Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Iv Acquisition 2 Lp 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Funds Gp Holdings Llc 10 percent owner 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Avista Healthcare Partners, L.p. 10 percent owner 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Brian A Markison director, officer: Chief Executive Officer 501 FIFTH STREET, BRISTOL TN 37620
Sriram Venkataraman director, 10 percent owner C/O AVISTA CAPITAL PARTNERS, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jeffrey Ferrell 10 percent owner ATHYRIUM CAPITAL MANAGEMENT, LP, 505 FIFTH AVENUE, FL 18, NEW YORK NY 10017
James Schaub officer: EVP and COO 400 CROSSING BOULEVARD, C/O OSMOTICA PHARMACEUTICALS PLC, BRIDGEWATER NJ 08807

RVL Pharmaceuticals (RVL Pharmaceuticals) Headlines